Pharmacy Benefits Management Services

Alerts

PBM WARNING LETTER: Sulfasalazine and Sulfadiazine LA/SA Errors

Warning Letter - Sulfasalazine-Sulfadiazine LA-SA Errors

Look-Alike Sound-Alike Confusion Potential with Humapen Memoir® and Humira® Pen – January 2007

Two Pens Different Uses; PBM Ez-Minutes January – March 2007
HUMIRA Pen and HumaPen; ISMP Newsletter April 2007

Look-Alike Sound-Alike Vaccine Mix-ups: Adacel (Tdap) and Daptacel (DTaP) – August 24, 2006

ISMP Newsletter

Fluarix® and Twinrix® Look-Alike Confusion Potential

National PBM Bulletin - Look-Alike Safety Alert Regarding Fluarix® and Twinrix®

LOOK-ALIKE SAFETY ALERT FOR HALOPERIDOL AND CYANOCOBALAMIN 1ML VIALS National PBM Bulletin 

Pilot Project for Determining Look-alike Sound-alike Drug Names for New Molecular Entities (NMEs)

LASA Draft Paper
Appendix I 
Appendix II 
Appendix III

VA-Specific LASA pairs

 VA LASA list 2020

Institute for Safe Medication Practice

ISMP Confused Drug Name

FDA LASA Alerts for 2011 

1. GENERAL SAFETY PROJECTS/PILOT PROJECTS
   1. Adverse Drug Event (ADE) Reporting
   2. Look-Alike Sound-Alike (LA/SA) Drug Names for New Molecular Entities (NMEs)
   3. Active Surveillance – Signal Detection
2. SITE-BASED MEDICATION SAFETY EVALUATIONS
   1. Conversion to and Initiation with Travoprost in Glaucoma Management
   2. Erythropoeitin Stimulating Agents (ESA) Database Medication Use Evaluation (MUE) Tracker
   3. Evaluation of Amiodarone Monitoring
3. RISK REDUCTION PROJECTS
   1. Glyburide Use in Patients with Renal Insufficiency
   2. High Dose Zolpidem
   3. High Dose Atypical Antipsychotic
4. DRUG SURVEILLANCE/PHARMACOVIGILANCE PROJECTS (Ongoing)
   1. Polypharmacy in Post Traumatic Stress Disorder (PTSD)
   2. Atypical Antipsychotic/SSRI/Benzodiazepine Rapid Cycle Analysis
   3. Varenicline Rapid Cycle Analysis
   4. PPIs Rapid Cycle Analysis
   5. Rapid Cycle Evaluation of Thiazolidinediones
   6. Long-Acting Opioids
   7. Bisphosphonates Pharmacovigilance-Rapid Analysis
   8. Rapid Cycle Analysis: Bevicizumab and Ranibizumab
   9. Rapid Cycle Signal Strengthening Evaluation: PPIs, H2Bs, and ACEs
   10. Rapid Cycle Analysis - Antiviral Drugs: Amantadine, Oseltamivir, Rimantadine, and Zanamivir
   11. Osteoporosis
   12. Vaccine Safety
   13. Influenza Project
   14. Risperidone
   15. Varenicline
   16. Beta-Blockers
   17. Glyburide
   18. Warfarin
   19. Fluoroquinolones

1. Rofecoxib (Vioxx®)
   1. PBM Bulletin/News Alert
   2. Physician Notification Letter
   3. Pharmacist Notification Letter
   4. Dear Healthcare Provider Letter
   5. FAQ’s
   6. Patient Letter
2. Valdecoxib (Bextra®)
   1. Guidance
   2. Patient Letter
3. Natalizumab (Tysabri®) – February 2005 - June 2006
   1. FDA Public Health Advisory
   2. FDA Alert – Information for Healthcare Professionals
   3. Dear Healthcare Professional Letter – March 2005
   4. Dear Healthcare Professional Letter – April 2005
   5. FAQ’s on the Clinical Hold
   6. FAQ’s on Natalizumab
   7. Prescribing Information
   8. PBM Removal Communication and Actions
   9. Important Drug Warning Letter from Biogen/Idec, Elan
   10. FDA Information on resumed market
4. Gatifloxacin (Tequin®)
   1. Letter of Discontinuation from Bristol Myers Squibb – May 2006
   2. FDA Alert – Information for Healthcare Professionals – March 2006
   3. FDA Alert – Patient Information – March 2006
   4. Prescribing Information
5. Mivacurium (Mivacron®)
   1. FDA Drug Shortages
6. Tegaserod (Zelnorm®) and Discontinued Marketing – March 30, 2007
   1. FDA News
   2. Questions and Answers on Zelnorm
   3. FDA Public Health Advisory
   4. National PBM Bulletin
   5. Tegaserod Provider Letter
   6. Tegaserod Patient Letter
   7. Restricted Use of Zelnorm – July 2007
7. FDA Recalls, Market Withdrawals, Safety Alerts